PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Jerome Ritz(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute), Robert Redd(Harvard University), Margaret A. Shipp(Broad Institute), Jeffrey L. Wong(Memorial Sloan Kettering Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Sanjay S. Patel(Brigham and Women's Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Erin Jeter(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Oreife O. Odejide, Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Kimberly C. Coleman(Dana-Farber Cancer Institute)
Cited by 65
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k